Alexander Rakitko

Alexander Rakitko


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in eClinicalMedicine
Verified
Journal Article
Open access
JWJanuary Weiner
January Weiner
PSPhillip Suwalski
Phillip Suwalski
MHManuel Holtgrewe
Manuel Holtgrewe
ARAlexandr Rakitko
Alexandr Rakitko
CTCharlotte Thibeault
Charlotte Thibeault
BHBettina Heidecker
Bettina Heidecker
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been increasing urgency to identify pathophysiological characteristics leading to severe clinical course in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen alleles (HLA) have been suggested as potential genetic host factors that affect individual immune response to SARS-CoV-2. We sought to evaluate this hypothesis by conducting a multicenter study using HLA sequencing. We analyzed the association between COVID-19 severity and HLAs in 435 individuals from Germany (n = 135), Spain (n = 133), Switzerland (n = 20) and the United States (n = 147), who had been enrolled from March 2020 to August 2020. This study included patients older than 18 years, diagnosed with COVID-19 and representing the full spectrum of the disease. Finally, we tested our results by meta-analysing data from prior genome-wide association studies (GWAS). We describe a potential association of HLA-C*04:01 with severe clinical course of COVID-19. Carriers of HLA-C*04:01 had twice the risk of intubation when infected with SARS-CoV-2 (risk ratio 1.5 [95% CI 1.1–2.1], odds ratio 3.5 [95% CI 1.9–6.6], adjusted p-value = 0.0074). These findings are based on data from four countries and corroborated by independent results from GWAS. Our findings are biologically plausible, as HLA-C*04:01 has fewer predicted bindings sites for relevant SARS-CoV-2 peptides compared to other HLA alleles. HLA-C*04:01 carrier state is associated with severe clinical course in SARS-CoV-2. Our findings suggest that HLA class I alleles have a relevant role in immune defense against SARS-CoV-2. Funded by Roche Sequencing Solutions, Inc.

21 May 2025 in Nature Genetics
Verified
Journal Article
Open access
VLVilma Lammi
Vilma Lammi
TNTomoko Nakanishi
Tomoko Nakanishi
SJSamuel E Jones
Samuel E Jones
SAShea J Andrews
Shea J Andrews
JKJuha Karjalainen
Juha Karjalainen
HOHanna M Ollila
Hanna M Ollila
Infections can lead to persistent symptoms and diseases such as shingles after varicella zoster or rheumatic fever after streptococcal infections. Similarly, severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection can result in long coronavirus disease (COVID), typically manifesting as fatigue, pulmonary symptoms and cognitive dysfunction. The biological mechanisms behind long COVID remain unclear. We performed a genome-wide association study for long COVID including up to 6,450 long COVID cases and 1,093,995 population controls from 24 studies across 16 countries. We discovered an association of FOXP4 with long COVID, independent of its previously identified association with severe COVID-19. The signal was replicated in 9,500 long COVID cases and 798,835 population controls. Given the transcription factor FOXP4’s role in lung physiology and pathology, our findings highlight the importance of lung function in the pathophysiology of long COVID.

1 July 2023 in medRxiv
Verified
Preprint
Open access
PDF file
VLVilma Lammi
Vilma Lammi
TNTomoko Nakanishi
Tomoko Nakanishi
SJSamuel E Jones
Samuel E Jones
SAShea J. Andrews
Shea J. Andrews
JKJuha Karjalainen
Juha Karjalainen
HOHanna M. Ollila
Hanna M. Ollila
Summary: Infections can lead to persistent or long-term symptoms and diseases such as shingles after varicella zoster, cancers after human papillomavirus, or rheumatic fever after streptococcal infections 1, 2 . Similarly, infection by SARS-CoV-2 can result in Long COVID, a condition characterized by symptoms of fatigue and pulmonary and cognitive dysfunction 3–5 . The biological mechanisms that contribute to the development of Long COVID remain to be clarified. We leveraged the COVID-19 Host Genetics Initiative 6, 7 to perform a genome-wide association study for Long COVID including up to 6,450 Long COVID cases and 1,093,995 population controls from 24 studies across 16 countries. We identified the first genome-wide significant association for Long COVID at the FOXP4 locus. FOXP4 has been previously associated with COVID-19 severity 6 , lung function 8 , and cancers 9 , suggesting a broader role for lung function in the pathophysiology of Long COVID. While we identify COVID-19 severity as a causal risk factor for Long COVID, the impact of the genetic risk factor located in the FOXP4 locus could not be solely explained by its association to severe COVID-19. Our findings further support the role of pulmonary dysfunction and COVID-19 severity in the development of Long COVID.

1 January 2017 in Physica D: Nonlinear Phenomena
Verified
Journal Article
Closed access
MTMichael Tsyrulnikov
Michael Tsyrulnikov
ARAlexandr Rakitko
Alexandr Rakitko

7 January 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
VPVladislav Perelygin
Vladislav Perelygin
AKAlexey Kamelin
Alexey Kamelin
NSNikita Syzrantsev
Nikita Syzrantsev
LSLayal Shaheen
Layal Shaheen
AKAnna Kim
Anna Kim
MPMaria Poptsova
Maria Poptsova
Background: Polygenic risk score (PRS) prediction is widely used to assess the risk of diagnosis and progression of many diseases. Routinely, the weights of individual SNPs are estimated by the linear regression model that assumes independent and linear contribution of each SNP to the phenotype. However, for complex multifactorial diseases such as Alzheimer’s disease, diabetes, cardiovascular disease, cancer, and others, association between individual SNPs and disease could be non-linear due to epistatic interactions. The aim of the presented study is to explore the power of non-linear machine learning algorithms and deep learning models to predict the risk of multifactorial diseases with epistasis.Methods: Simulated data with 2- and 3-loci interactions and tested three different models of epistasis: additive, multiplicative and threshold, were generated using the GAMETES. Penetrance tables were generated using PyTOXO package. For machine learning methods we used multilayer perceptron (MLP), convolutional neural network (CNN) and recurrent neural network (RNN), Lasso regression, random forest and gradient boosting models. Performance of machine learning models were assessed using accuracy, AUC-ROC, AUC-PR, recall, precision, and F1 score.Results: First, we tested ensemble tree methods and deep learning neural networks against LASSO linear regression model on simulated data with different types and strength of epistasis. The results showed that with the increase of strength of epistasis effect, non-linear models significantly outperform linear. Then the higher performance of non-linear models over linear was confirmed on real genetic data for multifactorial phenotypes such as obesity, type 1 diabetes, and psoriasis. From non-linear models, gradient boosting appeared to be the best model in obesity and psoriasis while deep learning methods significantly outperform linear approaches in type 1 diabetes.Conclusion: Overall, our study underscores the efficacy of non-linear models and deep learning approaches in more accurately accounting for the effects of epistasis in simulations with specific configurations and in the context of certain diseases.

29 December 2020 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Dmitry VerbenkoDmitry Verbenko
Dmitry Verbenko
AKArfenya Karamova
Arfenya Karamova
OAOlga Artamonova
Olga Artamonova
Dmitry DeryabinDmitry Deryabin
Dmitry Deryabin
ARAlexandr Rakitko
Alexandr Rakitko
AKAlexey A. Kubanov
Alexey A. Kubanov
One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies: IL1β (rs1143633), IL4 (IL13) (rs20541), IL23R (rs2201841), and TNFα (rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris.